ReviewInternational journal of nanomedicine2025
Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multiscale rational construction strategy for polyphenol self-assembled delivery systems: from nanoscale to microscale.Materials today. Bio · 2026Review
- Photoreceptor-targeted engineered exosomes encapsulating black phosphorus quantum dots for alleviating photoreceptor degeneration.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular diseases present unique therapeutic challenges due to the complex anatomical and physiological barriers of the eye. Conventional drug delivery systems often suffer from poor bioavailability, rapid clearance, and inadequate targeting, limiting their clinical efficacy. Recent advances in smart nano-in-micro (NIM) platforms have emerged as a transformative strategy, combining the precision of nanoscale drug carriers with the stability and sustained-release capabilities of microscale matrices. These hierarchical systems enable enhanced drug penetration, prolonged retention, and targeted delivery to both anterior and posterior ocular segments. This review highlights the latest developments in NIM platforms, focusing on material innovations that optimize drug loading, release kinetics, and biocompatibility. The shared physicochemical properties of nano-micro particles that influence their performance across different administration routes (topical, intravitreal, subconjunctival), supported by mechanistic insights into their interactions with ocular tissues are discussed. By bridging nanoscale engineering with clinical ophthalmology, NIM platforms represent a paradigm shift in ocular therapeutics, offering the potential to revolutionize treatment for previously intractable eye diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.